European Archives - Page 374 of 1013 - European Medical Journal

Claus Zieler on leadership

Claus Zieler, President of Established Markets at Astellas, speaks about the role leaders play in cultivating an enticing company culture

Meet GOLD's recent catalyst – Claus Zieler

In this episode, Helena and Marc are joined by Claus Zieler, President of Established Markets, Astellas, to discuss leadership and crisis management.

Management of HBV-liver transplant patients - Highlights from the ILTS congress 2022

Highlights from the International Liver Transplant Society (ILTS) Annual Meeting 2022 in Istanbul, and much more. Listen now!

Pharma in Brazil

Brazil has consistently appeared in the top 10 global pharmaceutical markets over the last decade and is making steady progress.

Medical affairs evolution and the future for MSLs

Marc, Helena and the team are joined by Luca Dezzani, Vice President, Oncology Medical Affairs, J&J, to talk all things medical affairs. Listen now!

Achieving first-time launch success

The first-time launch landscape is growing. In an increasing number of cases, it’s emerging biopharma and biotech companies launching new drugs rather than established pharma giants leading the way.

Incidentally Detected PET-CT Imaging Findings Of COVID-19 Pneumonia: A Retrospective Study During Local Pandemic Era

The novel COVID-19 pneumonia is a continuing global pandemic that has caused deaths of 5 million people worldwide as of November…

A Cross-Sectional Survey On the Psychological Effects of COVID-19 on Doctors and Non-doctors in Pakistan

Objective: The COVID-19 pandemic is still showing fluctuating trends and rapidly increasing case numbers, naturally creating a significant…

Men's Health Week special

In this Men’s Health Week special, the GOLD team is joined by Peter Baker, Director, Global Action on Men’s Health and Chumi Khurana, Global

Reverse mentoring: a how-to guide

Reverse mentoring challenges the status quo and flips traditional learning dynamics on their axis. This how-to guide deconstructs what must be considered when building a reverse mentoring scheme in pharma.